CareSens Air 3
i-SENS
What it is
An investigational i-SENS CGM identified in an adult T1D accuracy study. The registry still says recruiting despite an elapsed estimated completion date; no results or market authorization are established.
Editorial review: .
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Accuracy: Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 35 × 20 + 35 × 15 + 35 × 15 + 35 × 10 + 35 × 10 + 35 × 10 + 35 × 10 + 0 × 5 + 0 × 5 = 3150; divide by total weight 100. Unrounded weighted result: 31.5.
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Editor’s take
A named clinical development program merits tracking. Its specifications and relationship to Air2 remain unconfirmed; provisional scores must not be read as measured performance.
The full picture
CareSens Air 3 is named in i-SENS study NCT07296276, an adult T1D accuracy and precision study with estimated enrollment of 32. The record last updated 9 April 2026 still lists recruiting and an estimated completion of 30 April 2026. An elapsed forecast is not confirmation that recruitment or the study has finished; no results are posted.1
This record establishes the investigational device name, not an approved age indication, successful accuracy outcome or launch date. The available study record does not establish whether Air 3 is a renamed Air 2, a different platform or a regional variant, so these records remain separate.
Coming soon
ETA · No commercial launch date verified
Sources
- [1]NCT07296276 CareSens Air3 accuracy and precision study · Trial registry
ClinicalTrials.gov NCT07296276, checked 16 September 2026.